Characteristics of included randomised controlled trials
| Reference | Year | Participants screened(n) | Participants randomised (n) | Age range (years) | Interventions |
|---|---|---|---|---|---|
| BDP, beclomethasone dipropionate. | |||||
| Greening et al13 | 1994 | Not stated | 429 | >18 | Salmeterol/BDP v higher-dose BDP |
| Woolcock et al14 | 1996 | 990 | 738 | >17 | Salmeterol/BDP (2 different salmeterol doses) v higher-dose BDP |
| Pauwels et al15 | 1997 | 1114 | 852 | 18–70 | Formoterol/budesonide v budesonide (2 different budesonide doses in each group) |
| Busse et al16 | 1998 | Not stated | 473 | 18–70 | Budesonide (4 different doses) v placebo |
| Reed et al17 | 1998 | Not stated | 747 | 6–65 | BDP v theophylline |
| Wenzel et al18 | 1998 | Not stated | 539 | >12 | Salmeterol v albuterol |
| Laviolette et al19 | 1999 | Not stated | 642 | >15 | Montelukast/BDP v montelukast v BDP v placebo |
| Bleecker et al20 | 2000 | 592 | 451 | >12 | Fluticasone v zafirlukast |
| Nelson et al21 | 2000 | Not stated | 447 | >15 | Salmeterol/fluticasone v montelukast/fluticasone |
| Busse et al22 | 2001 | Not stated | 525 | 12–75 | Omalizumab v placebo |
| Fish et al23 | 2001 | Not stated | 948 | >15 | Salmeterol v montelukast |
| O’Byrne et al24 | 2001 | 2525 | 1970 | >12 | Formoterol/budesonide v budesonide v placebo and formoterol/budesonide v budesonide (2 different budesonide doses in each group) |
| Lalloo et al25 | 2003 | 494 | 467 | >15 | Formoterol/budesonide v higher-dose budesonide |
| Pauwels et al26 | 2003 | Not stated | 7241 | 5–66 | Budesonide v placebo |
| Price et al27 | 2003 | 1192 | 889 | 15–75 | Montelukast/budesonide v higher-dose budesonide |
| Ringdal et al28 | 2003 | 1168 | 806 | >15 | Salmeterol/fluticasone v montelukast/fluticasone |
| Vaquerizo et al29 | 2003 | 846 | 639 | 18–70 | Montelukast/budesonide v budesonide |